Evidence mapPaperPMID 40807276Full record

ReviewMolecules (Basel, Switzerland)2025

Research Progress and Prospects of Flavonoids in the Treatment of Hyperlipidemia: A Narrative Review.

Xingtong Chen, Jinbiao Yang, Yunyue Zhou, Qiao Wang, Shuang Xue, Yukun Zhang, Wenying Niu

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Research Status and Latest Progress in the Regulatory Mechanisms of ABCA1.International journal of molecular sciences · 2025
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xingtong ChenSchool of Basic Medical Sciences, Heilongjiang University of Chinese Medicine, Harbin 150040, China.
Jinbiao YangSchool of Basic Medical Sciences, Heilongjiang University of Chinese Medicine, Harbin 150040, China.
Yunyue ZhouSchool of Basic Medical Sciences, Heilongjiang University of Chinese Medicine, Harbin 150040, China.
Qiao WangSchool of Basic Medical Sciences, Heilongjiang University of Chinese Medicine, Harbin 150040, China.
Shuang XueSchool of Basic Medical Sciences, Heilongjiang University of Chinese Medicine, Harbin 150040, China.
Yukun ZhangSchool of Basic Medical Sciences, Heilongjiang University of Chinese Medicine, Harbin 150040, China.
Wenying NiuSchool of Basic Medical Sciences, Heilongjiang University of Chinese Medicine, Harbin 150040, China.

Funding

"Basic Research Support Program for Outstanding Young Teachers" of Heilongjiang Provincial Undergraduate Universities YQJH2024227National Natural Science Foundation of China 82274405
6 · The paper itself

Abstract

Hyperlipidemia (HLP) is a disorder of human lipid metabolism or transport, primarily characterized by abnormally elevated levels of total cholesterol (TC), triglycerides (TGs), and low-density lipoprotein cholesterol (LDL-C) in the blood. It is a key factor contributing to the development of non-alcoholic fatty liver disease, obesity, diabetes, atherosclerosis, and cardiovascular and cerebrovascular diseases. Statistics show that the prevalence of dyslipidemia among Chinese adults is as high as 35.6%, and it has shown a trend of younger onset in recent years, posing a serious threat to public health. Therefore, the prevention and treatment of dyslipidemia carry significant social significance. The pathogenesis of hyperlipidemia is complex and diverse, and currently used medications are often accompanied by side effects during treatment, making the research and development of new therapeutic approaches a current focus. Numerous studies have shown that flavonoids, which are abundant in most medicinal plants, fruits, and vegetables, exert effects on regulating lipid homeostasis and treating hyperlipidemia through a multi-target mechanism. These compounds have demonstrated significant effects in inhibiting lipid synthesis, blocking lipid absorption, promoting cholesterol uptake, enhancing reverse cholesterol transport, and suppressing oxidative stress, inflammation, and intestinal microbiota disorders. This article reviews the latest progress in the mechanisms of flavonoids in the treatment of hyperlipidemia, providing a theoretical basis for future research on drugs for hyperlipidemia.

Indexed as

FlavonoidsHyperlipidemiasHypolipidemic AgentsAnimalsHumansLipid MetabolismFlavonoidsHypolipidemic Agentsflavonoidshyperlipidemialipid metabolismresearch progress

Identifiers

PMID40807276
PMCPMC12348653

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.